Understanding the molecular basis and oncogenic drivers of cancer, such as EGFR, KRAS, and BRAF mutations, is crucial to providing targeted therapies for cancer patients (54) EGFR mutations are found in 10%-20% of lung adenocarcinoma cases (55) and are predictive of NSCLC response to erlotinib (56), a target drug that inhibits the tyrosine kinase activity of EGFR. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.